| Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients (NCT04159818) | The Netherlands Cancer Institute | 2020-02-21 |
| A Study of TAS-120 in Patients With Metastatic Breast Cancer (NCT04024436) | Taiho Oncology, Inc. | 2020-01-28 |
| Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) (NCT04020575) | Minerva Biotechnologies Corporation | 2020-01-15 |
| Effects of Exercise in Patients With Metastatic Breast Cancer (NCT04120298) | UMC Utrecht | 2020-01-08 |
| Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer. (NCT04265274) | National Cancer Institute, Slovakia | 2020-01-01 |
| Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer (NCT04246502) | Shandong Cancer Hospital and Institute | 2020-01-01 |
| Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer (NCT04165993) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2019-12-31 |
| A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (NCT04188548) | Eli Lilly and Company | 2019-12-10 |
| Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer (NCT03698383) | Korean Cancer Study Group | 2019-12-03 |
| Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study (NCT04170634) | Hospices Civils de Lyon | 2019-11-28 |
| Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB (NCT04129346) | Northwestern University | 2019-11-26 |
| Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer (NCT04115306) | Phoenix Molecular Designs | 2019-11-14 |
| Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (NCT04042051) | Cancer Trials Ireland | 2019-11-12 |
| Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer (NCT04407988) | Hunan Cancer Hospital | 2019-11-06 |
| Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer (NCT04088110) | Fuzhou General Hospital | 2019-11-01 |
| Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention (NCT04092816) | UNC Lineberger Comprehensive Cancer Center | 2019-10-30 |
| Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer (NCT04143906) | Shandong Cancer Hospital and Institute | 2019-10-25 |
| Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment (NCT04143282) | Hager salah el din | 2019-10-20 |
| A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer (NCT04095390) | Jinming Yu | 2019-09-30 |
| A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer (NCT03988114) | Eli Lilly and Company | 2019-09-16 |
| Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone (NCT06321666) | European Institute of Oncology | 2019-09-12 |
| Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer (NCT03368729) | University of Alabama at Birmingham | 2019-09-06 |
| Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases (NCT03970967) | Alpha Tau Medical LTD. | 2019-08-28 |
| A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (NCT03997539) | Sun Yat-sen University | 2019-08-15 |
| Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer (NCT03993964) | Sun Yat-sen University | 2019-08-15 |
| A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer (NCT04031885) | Eli Lilly and Company | 2019-08-14 |
| A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body (NCT03955939) | Eli Lilly and Company | 2019-08-02 |
| Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer (NCT04061863) | Seoul National University Hospital | 2019-08-01 |
| Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer (NCT04030507) | Brigham and Women's Hospital | 2019-07-26 |
| Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer (NCT04034589) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2019-07-17 |
| Genetic Characteristics of Metastatic Breast Cancer Patients (NCT04258735) | Samsung Medical Center | 2019-07-17 |
| Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy (NCT04318223) | Consorzio Oncotech | 2019-07-16 |
| Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer (NCT04001621) | Fudan University | 2019-06-26 |
| Telephone Support for Metastatic Breast Cancer Patients (NCT03998618) | Indiana University | 2019-06-20 |
| Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (NCT03910712) | Peking Union Medical College Hospital | 2019-06-01 |
| Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer (NCT03786094) | Spexis AG | 2019-05-30 |
| B002 in Patients With HER2-positive Breast Cancer (NCT04382352) | Shanghai Pharmaceuticals Holding Co., Ltd | 2019-05-28 |
| ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer (NCT03950570) | Orinove, Inc. | 2019-05-25 |
| Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (NCT03901339) | Gilead Sciences | 2019-05-08 |
| PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer (NCT02917005) | Hamdy A. Azim | 2019-05-07 |
| Optimizing Quality of Life in Women Living With Metastatic Breast Cancer (NCT04374825) | Northwestern University | 2019-04-24 |
| A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer (NCT03863223) | Jiangsu HengRui Medicine Co., Ltd. | 2019-04-22 |
| Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer (NCT03591276) | Shaare Zedek Medical Center | 2019-04-18 |
| Safety and Pharmacokinetics of ODM-209 (NCT03878823) | Orion Corporation, Orion Pharma | 2019-04-17 |
| Vaccination With Flt3L, Radiation, and Poly-ICLC (NCT03789097) | Icahn School of Medicine at Mount Sinai | 2019-04-05 |
| WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor (NCT03854903) | Georgetown University | 2019-04-01 |
| Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer (NCT03644589) | University of Washington | 2019-04-01 |
| Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma (NCT03787303) | Aultman Health Foundation | 2019-03-01 |
| Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC (NCT03876587) | Zhejiang Cancer Hospital | 2019-03-01 |
| Nurse AMIE: Addressing Metastatic Individuals Everyday (NCT03975621) | Milton S. Hershey Medical Center | 2019-03-01 |
| Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer (NCT03892096) | Cadex Genomics | 2019-03-01 |
| Eribulin in Brain Metastases From HER2-negative Breast Cancer (NCT03637868) | Institut Paoli-Calmettes | 2019-02-26 |
| Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD (NCT03501979) | University of Alabama at Birmingham | 2019-02-20 |
| Pain Phenotyping of Patients With Bone Cancer Pain (NCT03908853) | University of Copenhagen | 2019-02-05 |
| Determinants of Acquired Endocrine Resistance in Metastatic Breast Cancer: A Pilot Study (NCT04579484) | Sunnybrook Health Sciences Centre | 2019-02-04 |
| Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer (NCT04247035) | Hellenic Society of Medical Oncology | 2019-01-31 |
| Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases (NCT03807765) | H. Lee Moffitt Cancer Center and Research Institute | 2019-01-30 |
| ModraDoc006/r in Patients With Breast Cancer (NCT03890744) | Modra Pharmaceuticals | 2019-01-30 |
| A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy (NCT03473639) | University of Virginia | 2019-01-29 |
| Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy (NCT04176354) | Pfizer | 2019-01-25 |
| Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec) (NCT03758976) | Lund University Hospital | 2019-01-21 |
| Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease (NCT03808337) | Memorial Sloan Kettering Cancer Center | 2019-01-16 |
| Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica (NCT04163159) | Universidad de Costa Rica | 2019-01-07 |
| Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy (NCT04258163) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2019-01-01 |
| Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers (NCT03323424) | Institut de Cancérologie de la Loire | 2019-01-01 |
| Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer (NCT03755141) | National Cancer Center, Korea | 2018-12-15 |
| Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA) (NCT03732391) | CORTESI LAURA | 2018-12-12 |
| T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (NCT03530696) | University of Arizona | 2018-12-06 |
| A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer (NCT03703466) | Eli Lilly and Company | 2018-11-28 |
| Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients (NCT03449238) | Weill Medical College of Cornell University | 2018-11-15 |
| Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial) (NCT05735392) | Consorzio Oncotech | 2018-11-07 |
| Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study (NCT04012918) | Ain Shams University | 2018-08-30 |
| Fulvestrant in Metastatic Breast Cancer (NCT03591549) | Assiut University | 2018-08-01 |
| Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients (NCT05833919) | Consorzio Oncotech | 2018-07-30 |
| Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases (NCT03143322) | UNICANCER | 2018-07-24 |
| Study to Evaluate CCS1477 in Advanced Tumours (NCT03568656) | CellCentric Ltd. | 2018-07-23 |
| A Whole-food, Plant-Based Nutrition Intervention in Women With Metastatic Breast Cancer (NCT03045289) | University of Rochester | 2018-07-05 |
| Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP (NCT03562832) | Allarity Therapeutics | 2018-06-20 |
| G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer (NCT03455270) | G1 Therapeutics, Inc. | 2018-05-09 |
| Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer (NCT04263298) | Herui Yao | 2018-05-01 |
| Olaparib In Metastatic Breast Cancer (NCT03344965) | Beth Israel Deaconess Medical Center | 2018-04-01 |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (NCT03424005) | Hoffmann-La Roche | 2018-03-30 |
| Combination Study of SV-BR-1-GM With Retifanlimab (NCT03328026) | BriaCell Therapeutics Corporation | 2018-03-16 |
| A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (NCT03355157) | GBG Forschungs GmbH | 2018-03-01 |
| Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins (NCT02965755) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-01-26 |
| Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer (NCT03409198) | Oslo University Hospital | 2018-01-21 |
| S 81694 Plus Paclitaxel in Metastatic Breast Cancer (NCT03411161) | Institut de Recherches Internationales Servier | 2018-01-04 |
| Hypo-Fractionated Radiotherapy in Breast Cancer (NCT03669497) | Tata Medical Center | 2018-01-02 |
| Her2-BATS and Pembrolizumab in Metastatic Breast Cancer (NCT03272334) | University of Virginia | 2017-12-29 |
| SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (NCT03262935) | Byondis B.V. | 2017-12-15 |
| PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer (NCT03362060) | Massachusetts General Hospital | 2017-12-12 |
| A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers (NCT03251378) | Hutchison Medipharma Limited | 2017-12-11 |
| Nurse AMIE: A Tablet Based Supportive Care Platform in Metastatic Breast Cancer (NCT03456973) | Milton S. Hershey Medical Center | 2017-10-01 |
| Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer (NCT03323346) | The Institute of Molecular and Translational Medicine, Czech Republic | 2017-09-29 |
| Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing (NCT03608865) | Yonsei University | 2017-09-19 |
| Palbociclib After CDK and Endocrine Therapy (PACE) (NCT03147287) | Dana-Farber Cancer Institute | 2017-09-05 |
| Molecular Evaluation in Metastatic Breast Cancer (NCT03358589) | Odense University Hospital | 2017-09-01 |
| Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer (NCT03238196) | Vanderbilt-Ingram Cancer Center | 2017-08-18 |
| An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer (NCT03505528) | EpiAxis Therapeutics | 2017-08-17 |
| Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (NCT03241810) | Elevation Oncology | 2017-08-15 |